Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. | ![]() 5Y returns in the bottom 25% of the category. |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 88 Cr | 8357 Cr | ||
Min Investment | SIP ₹200 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.22% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 31 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (9.72%) Apollo Hospitals Enterprise Ltd (5.79%) Cipla Ltd (5.62%) Torrent Pharmaceuticals Ltd (5.29%) Fortis Healthcare Ltd (4.35%) | Sun Pharmaceuticals Industries Ltd (11.94%) Divi's Laboratories Ltd (7.34%) Cipla Ltd (6.09%) Lupin Ltd (6.09%) Apollo Hospitals Enterprise Ltd (5.91%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (92.67%) Basic Materials (7.33%) | Health (100%) | ||
Equity % | 94.35% | 99.48% | ||
Debt % | - | - | ||
P/E | 43.25 | 36.11 | ||
P/B | 5.9 | 5.78 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.11% | 2.11% | ||
3-Month Return | 3.61% | 1.06% | ||
6-Month Return | 11.64% | 12.22% | ||
1-Year Return | 0.84% | -0.74% | ||
3-Year Return | 21.72% | 23.99% | ||
5-Year Return | 16.4% | 20.18% |
Sharpe | 0.89 | 1.06 | ||
Alpha | -1.8 | 0.66 | ||
Beta | 0.93 | 0.91 | ||
Standard Deviation | 15.56 | 15.05 | ||
Information Ratio | -0.82 | -0.24 |
Description | LIC MF Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Karan Doshi | Sailesh Raj Bhan,Kinjal Desai |